Listen again · In Conversation
Health explained: Zolgensma and tumor reports
· 3:27 · With Maya and Grace
Grace, Novartis says it has received reports of tumors in children who were treated with Zolgensma.
Transcript
Vocabulary in this episode
- evidence
This is Health Explained, where we look at health questions and what the evidence says.
Information that helps show whether something is true.
- evidence
In two cases, doctors found evidence that genetic material from the treatment had entered the patients’ DNA.
Information suggesting that genetic material entered the patients’ DNA.
- evidence
In two cases, doctors found evidence that genetic material from the virus carrier had become part of the patients’ DNA.
Information suggesting that the genetic material joined the patients’ DNA.
- evidence
The company described it as evidence of a possible link to the tumors, not proof that the therapy caused every tumor in the nine reports.
Information suggesting a possible connection, but not proving that the therapy caused the tumors.
- evidence
MedPage Today reports, citing SMA Europe, that regulators were assessing the available evidence.
The information regulators were considering.
- evidence
The reports raise a safety concern: Novartis said doctors found evidence that the treatment’s virus carrier had placed genetic material into patients’ DNA in two cases.
Information suggesting that the genetic material entered patients’ DNA.
- evidence
The key question is how the evidence develops and what it means for children who have received the therapy.
The information available about the treatment and possible tumors.
- gene therapy
It is a one-time gene therapy for spinal muscular atrophy, or SMA, in children younger than two.
A treatment that works by changing or adding genetic material.
- spinal muscular atrophy
It is a one-time gene therapy for spinal muscular atrophy, or SMA, in children younger than two.
A disease that affects muscles and movement.
- modified virus
Zolgensma uses a modified virus to carry a working copy of a gene into cells.
A virus changed so it can carry a gene into the body’s cells.
- integration
That is called integration.
The joining of genetic material with a patient’s DNA.
- health authorities
What has the company said about notifying health authorities, and what does the report say about regulators?
Government or public bodies responsible for health matters.
- health authorities
Novartis says it notified health authorities in both cases.
Government or public bodies responsible for health matters.
- prescribing information
The report also says the potential tumor risk is already included in Zolgensma’s prescribing information, the document that explains how the medicine is used and its risks.
The official document explaining how to use the medicine and what risks it may have.
- prescribing information
Families and clinicians can look to the medicine’s prescribing information and the assessments regulators are making.
The document that explains how the medicine is used and what risks it may have.